论文信息 - First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). - 字舞流文

First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).

J. Witjes | M. Galsky | D. Bajorin | S. Park | S. Shariat | D. Zardavas | Y. Tomita | K. Unsal-Kaçmaz | D. Ye | S. Collette | T. Lebret | A. Bamias | J. Gschwend | M. Schenker | M. Agerbæk | H. Koon | B. Valderrama